Home
  • Clinical Trials
  • Partnerships
  • Contact Us
  • News
  • Careers
  • About Us
    • Management Team
    • Board of Directors
    • Scientific and Clinical Advisory Boards
    • Commercial Advisory Board
  • Our Focus
    • Infectious Disease
    • Oncology
  • Our Pipeline
    • Prophylactic
    • Therapeutic
    • Clinical Trials
  • Our Science and Technology
  • Investors
    • Press Releases
    • Events and Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • About Us
    • Management Team
    • Board of Directors
    • Scientific and Clinical Advisory Boards
    • Commercial Advisory Board
  • Our Focus
    • Infectious Diseases
    • Oncology
  • Our Pipeline
    • Prophylactic
    • Therapeutic
    • Clinical Trials
  • Our Science and Technology
  • News and Resources
    • News
    • Posters
    • Videos
    • Publications
  • Investors
    • Press Releases
    • Company Information
    • Corporate Governance
    • Events and Presentations
    • SEC Filings
    • Stock Information
  • Careers
  • Partnerships
  • Contact Us
Search our website

World Vaccine Congress Europe 2019

October 29, 2019 |

View More

February 2, 2021

VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine


January 21, 2021

VBI Vaccines Announces Progress of Coronavirus Vaccine Program


January 15, 2021

VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine


December 23, 2020

VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B Vaccine


December 7, 2020

VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine


December 2, 2020

VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James


December 1, 2020

VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine


November 23, 2020

VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency


Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top
Navigate
  • About Us
  • Our Focus
  • Our Science and Technology
  • Our Pipeline
  • Investors
  • Clinical Trials
  • Contact Us
About Us
  • Management Team
  • Board of Directors
  • Scientific and Clinical Advisory Boards
  • Commercial Advisory Board
  • Partnerships
  • News and Resources
  • Careers
Connect With Us
  • Twitter Icon
  • Facebook Icon
  • YouTube Icon
  • LinkedIn Icon
VBI Logo Home

© 2021 VBI Vaccines Inc. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Site Map
  • Contact Us